Faron confirms plans under new leadership
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron confirms plans for the coming months under new leadership - Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month - Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA Press Release, April 16, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT) TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-